As 4-1BB+ PD1hi CD8+ TILs are hypothesised to be tumour-reactive T cells, 4-1BB costimulation using agonistic antibodies may be promising anti-tumour strategy in HCC patients (92). This evidence concerns the gene CD8A and hepatocellular carcinoma.